The fund tracks the Robo Global Healthcare Technology and Innovation Index. Using index rules, it selects companies that earn part of their business and revenue from medical technology and have room to grow as their products and services gain market adoption.

It suits long-term investors who find it burdensome to pick individual medical technology companies and want to spread a healthcare innovation theme across several countries.

It is a passive (index-tracking) ETF managed by Robo Global.

The fund invests most of its assets in the index's constituent stocks or in depositary receipts representing those stocks. Instead of market-cap weighting, it uses a modified factor approach to reduce reliance on mega-cap stocks, and it rebuilds the index every quarter to reflect technological change and shifts in the competitive landscape.

• A structure that spreads holdings across several sub-sectors, including medical devices, diagnostics, genomics and healthcare data
• Modified factor weighting rather than market-cap weighting, which reduces concentration in top holdings
• A global makeup that includes companies listed in many countries, not just the US

Assets under management (AUM) stand at $111.2M, and the total expense ratio is 0.68% per year.

It holds fewer stocks and has a stronger growth tilt than funds that track broad healthcare indexes, so even within healthcare, its price behavior has a different character.

The medical technology theme is sensitive to interest rates and investor appetite for growth stocks, so it tends to swing more widely than broad healthcare indexes. Its strong and weak stretches depend on new product approvals and trends in healthcare spending.

As with any thematic ETF, fund flows rise and fall with interest in the theme. Because the fund is smaller than core healthcare products, flows in and out also have a relatively larger effect on bid-ask spreads.

Its strength is that it diversifies across the medical technology innovation theme in a single holding. Its weaknesses are the cost burden and the volatility that comes with thematic concentration.

IXJ(ETF), which appears alongside it in the table, is a core product covering global healthcare broadly, in contrast to this ETF's thematic focus. Other sector products such as IXN, IXC and PICK invest in different areas and cannot be treated as the same category, so they are useful only as a reference for comparing expense levels and fund size. For US healthcare broadly, you can compare XLV; for a medical device focus, IHI; for biotech, IBB; for genomic innovation, ARKG; and for equal-weighted healthcare equipment, XHE.

These are the items to review before buying this ETF. Thematic products differ from core products on three points: expense ratio, liquidity and concentration. Judging only by the shared name "healthcare" and treating it the same as a core product makes it easy to underestimate volatility.

When enthusiasm for the theme cools, drawdowns run deeper than for broad healthcare indexes. Regulatory changes, reduced healthcare spending and delays in new product approvals also flow straight into earnings. Currency fluctuations separately affect returns in Korean won.

It is worth considering if you want to hold the healthcare innovation theme as a satellite asset. If cost and liquidity come first, consider a core product such as IXJ; if you want to narrow your exposure to specific sub-sectors, we recommend comparing options such as IHI and IBB.